×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
AMGN – amgen inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
AMGN
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
4/17
09:57 am
amgn
Amgen Inc. (AMGN): Among the Innovative Healthcare Stocks to Watch in 2025 [Yahoo! Finance]
Low
Report
Amgen Inc. (AMGN): Among the Innovative Healthcare Stocks to Watch in 2025 [Yahoo! Finance]
4/17
08:07 am
amgn
Injectable Drug Delivery Devices Market Set to Reach $317.2 Billion by 2029 [Yahoo! Finance]
Low
Report
Injectable Drug Delivery Devices Market Set to Reach $317.2 Billion by 2029 [Yahoo! Finance]
4/17
02:37 am
amgn
Amgen Inc. (NASDAQ: AMGN) was downgraded by analysts at StockNews.com from a "strong-buy" rating to a "buy" rating.
Low
Report
Amgen Inc. (NASDAQ: AMGN) was downgraded by analysts at StockNews.com from a "strong-buy" rating to a "buy" rating.
4/16
04:43 pm
amgn
Stocks rocked after Fed's Powell talks tariff impact [FOX Business Network]
Low
Report
Stocks rocked after Fed's Powell talks tariff impact [FOX Business Network]
4/16
08:13 am
amgn
KRAS Inhibitors Market Research and Forecasts 2025-2030: Lumakras, Krazati, Dupert, Anfangning Drug Sales, Patent, Price & Clinical Trials Insights [Yahoo! Finance]
Medium
Report
KRAS Inhibitors Market Research and Forecasts 2025-2030: Lumakras, Krazati, Dupert, Anfangning Drug Sales, Patent, Price & Clinical Trials Insights [Yahoo! Finance]
4/16
05:13 am
amgn
Pruritus Therapeutics Market Analysis and Forecast 2025-2034 | Biologics and JAK Inhibitors Drive Innovation in Pruritus Care, Offering Targeted Relief and Long-term Efficacy [Yahoo! Finance]
Medium
Report
Pruritus Therapeutics Market Analysis and Forecast 2025-2034 | Biologics and JAK Inhibitors Drive Innovation in Pruritus Care, Offering Targeted Relief and Long-term Efficacy [Yahoo! Finance]
4/14
05:57 pm
amgn
Amgen Inc. (NASDAQ: AMGN) had its price target raised by analysts at UBS Group AG from $315.00 to $319.00. They now have a "neutral" rating on the stock.
Low
Report
Amgen Inc. (NASDAQ: AMGN) had its price target raised by analysts at UBS Group AG from $315.00 to $319.00. They now have a "neutral" rating on the stock.
4/14
10:14 am
amgn
[Corrected] Sandoz files antitrust litigation against Amgen regarding patient access to etanercept biosimilar in the US [Yahoo! Finance]
Low
Report
[Corrected] Sandoz files antitrust litigation against Amgen regarding patient access to etanercept biosimilar in the US [Yahoo! Finance]
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
4/17
09:37 am
amgn
Form SCHEDULE 13G/A AMGEN INC Filed by: BlackRock, Inc.
Low
Report
Form SCHEDULE 13G/A AMGEN INC Filed by: BlackRock, Inc.
4/16
12:44 pm
amgn
Form PX14A6G AMGEN INC Filed by: Chevedden John
Low
Report
Form PX14A6G AMGEN INC Filed by: Chevedden John
4/9
08:32 am
amgn
Form DEF 14A AMGEN INC For: May 23
Medium
Report
Form DEF 14A AMGEN INC For: May 23
3/19
08:23 pm
amgn
Form 4 AMGEN INC For: Mar 17 Filed by: Santos Esteban
Low
Report
Form 4 AMGEN INC For: Mar 17 Filed by: Santos Esteban
3/19
08:22 pm
amgn
Form 4 AMGEN INC For: Mar 17 Filed by: REESE DAVID M
Low
Report
Form 4 AMGEN INC For: Mar 17 Filed by: REESE DAVID M
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
3/23
Amgen And The Amgen Foundation Commit Up To $12.5 Million To Support COVID-19 Relief Efforts
8.8%
8/8 Form 4 AMGEN INC For: Aug 07 Filed by: SUGAR RONALD D 6.2%
7/30 Amgen Reports Second Quarter 2019 Financial Results 6.1%
4/2 Amgen And Adaptive Biotechnologies Announce Strategic Partnership To Develop A Therapeutic To Prevent Or Treat COVID-19 6.0%
8/26 UPDATE 2-Amgen to buy Celgene's psoriasis drug Otezla for $13.4 bln in cash [Reuters (UK)] 5.9%
4/7 Biotech Giant Amgen Entered The Coronavirus Arena — But Is It A Buy? [Investor's Business Daily] 5.9%
3/28 Amgen Announces Positive Results At ACC.20/WCC From Phase 3B Study Of Repatha® (Evolocumab) In People Living With HIV Who Have High LDL-Cholesterol 5.2%
8/12 Amgen, Inc. (NASDAQ: AMGN) had its "positive" rating re-affirmed by analysts at Wells Fargo & Co. They now have a $202.00 price target on the stock, up previously from $197.00. 5.0%
3/13 Amgen, Inc. (NASDAQ: AMGN) was upgraded by analysts at Cfra from a "hold" rating to a "buy" rating. 4.1%
3/26 Amgen, Inc. (NASDAQ: AMGN) had its price target lowered by analysts at Oppenheimer Holdings Inc. from $250.00 to $240.00. They now have an "outperform" rating on the stock. 3.1%
8/8 Form 4 AMGEN INC For: Aug 07 Filed by: SUGAR RONALD D 6.2%
7/30 Amgen Reports Second Quarter 2019 Financial Results 6.1%
4/2 Amgen And Adaptive Biotechnologies Announce Strategic Partnership To Develop A Therapeutic To Prevent Or Treat COVID-19 6.0%
8/26 UPDATE 2-Amgen to buy Celgene's psoriasis drug Otezla for $13.4 bln in cash [Reuters (UK)] 5.9%
4/7 Biotech Giant Amgen Entered The Coronavirus Arena — But Is It A Buy? [Investor's Business Daily] 5.9%
3/28 Amgen Announces Positive Results At ACC.20/WCC From Phase 3B Study Of Repatha® (Evolocumab) In People Living With HIV Who Have High LDL-Cholesterol 5.2%
8/12 Amgen, Inc. (NASDAQ: AMGN) had its "positive" rating re-affirmed by analysts at Wells Fargo & Co. They now have a $202.00 price target on the stock, up previously from $197.00. 5.0%
3/13 Amgen, Inc. (NASDAQ: AMGN) was upgraded by analysts at Cfra from a "hold" rating to a "buy" rating. 4.1%
3/26 Amgen, Inc. (NASDAQ: AMGN) had its price target lowered by analysts at Oppenheimer Holdings Inc. from $250.00 to $240.00. They now have an "outperform" rating on the stock. 3.1%
TOP News Decliners
3/14
Amgen, Inc. (NASDAQ: AMGN) was upgraded by analysts at BidaskClub from a "sell" rating to a "hold" rating.
-6.8%
3/7 Hedge Funds Have Never Been This Bullish On NVIDIA Corporation (NVDA) [Yahoo! Finance News] -5.8%
2/27 Amgen, Inc. (NASDAQ: AMGN) is now covered by analysts at Barclays PLC. They set an "equal weight" rating on the stock. -5.1%
3/24 Form 4 AMGEN INC For: Mar 20 Filed by: REESE DAVID M -4.6%
4/30 Form 8-K AMGEN INC For: Apr 30 -4.6%
1/30 Q4/2019 12/31/2019 EPS 3.640 ZacksConsensus 3.470 ActVsEst 0.170 - Beat -4.5%
2/25 Amgen Stock Is Forming A Flat Base — Is It Time To Bet On AMGN Stock? [Investor's Business Daily] -3.8%
8/2 Form 4 AMGEN INC For: Aug 01 Filed by: Santos Esteban -3.1%
3/10 Form 4 AMGEN INC For: Mar 09 Filed by: REESE DAVID M -2.8%
3/31 Form 8-K AMGEN INC For: Mar 31 -2.8%
3/7 Hedge Funds Have Never Been This Bullish On NVIDIA Corporation (NVDA) [Yahoo! Finance News] -5.8%
2/27 Amgen, Inc. (NASDAQ: AMGN) is now covered by analysts at Barclays PLC. They set an "equal weight" rating on the stock. -5.1%
3/24 Form 4 AMGEN INC For: Mar 20 Filed by: REESE DAVID M -4.6%
4/30 Form 8-K AMGEN INC For: Apr 30 -4.6%
1/30 Q4/2019 12/31/2019 EPS 3.640 ZacksConsensus 3.470 ActVsEst 0.170 - Beat -4.5%
2/25 Amgen Stock Is Forming A Flat Base — Is It Time To Bet On AMGN Stock? [Investor's Business Daily] -3.8%
8/2 Form 4 AMGEN INC For: Aug 01 Filed by: Santos Esteban -3.1%
3/10 Form 4 AMGEN INC For: Mar 09 Filed by: REESE DAVID M -2.8%
3/31 Form 8-K AMGEN INC For: Mar 31 -2.8%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: